China's National Medical Products Administration accepted CanSino Biologics' (HKG:6185, SHA:688185) supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.
Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.
Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。